95 related articles for article (PubMed ID: 18448563)
1. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Ray-Coquard I; Le Cesne A; Whelan JS; Schoffski P; Bui BN; Verweij J; Marreaud S; van Glabbeke M; Hogendoorn P; Blay JY
Oncologist; 2008 Apr; 13(4):467-73. PubMed ID: 18448563
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
5. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
6. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Moore AM; Einhorn LH; Estes D; Govindan R; Axelson J; Vinson J; Breen TE; Yu M; Hanna NH
Lung Cancer; 2006 Apr; 52(1):93-7. PubMed ID: 16488055
[TBL] [Abstract][Full Text] [Related]
9. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
[TBL] [Abstract][Full Text] [Related]
13. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Reichardt P; Nielsen OS; Bauer S; Hartmann JT; Schöffski P; Christensen TB; Pink D; Daugaard S; Marreaud S; Van Glabbeke M; Blay JY;
Eur J Cancer; 2007 Apr; 43(6):1017-22. PubMed ID: 17336054
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano G; De Braud F; Teresa Sandri M; Renne G; Zorzino L; Scardino E; Rocco B; Spitaleri G; De Pas T; Noberasco C; Nolè F; Verweij F; Matei V; De Cobelli O
Anticancer Drugs; 2007 Sep; 18(8):949-54. PubMed ID: 17667601
[TBL] [Abstract][Full Text] [Related]
16. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
von Minckwitz G; Jonat W; Fasching P; du Bois A; Kleeberg U; Lück HJ; Kettner E; Hilfrich J; Eiermann W; Torode J; Schneeweiss A
Breast Cancer Res Treat; 2005 Jan; 89(2):165-72. PubMed ID: 15692759
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.
Blay JY; Judson I; Rodenhuis S; Hermans C; Smith M; van Glabbeke M; Verweij J
Anticancer Drugs; 1999 Nov; 10(10):873-7. PubMed ID: 10630354
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]